Dr. Nigel Stevenson from Exubrion Therapeutics® and Vivos Inc CEO Dr. Mike Korenko have just submitted a joint abstract entitled “Precision Radionuclide Therapy for Treating Veterinary Cancerous Tumors and Osteoarthritis” to the 11th International Conference on Isotopes on July 23-24 in Saskatoon, SK Canada.
Nigel is Exubrion Therapeutics’ Chief Operations Officer and is also the Vivos Inc Chief Science Advisor. The two companies cooperate since they are in totally different therapy markets. The CEOs of both companies decided that it is in their best interest to promote the benefits of precision radionuclide therapy.
Write a comment